Tuesday - August 25, 2026
GSK: Hibsago Approved in Japan as First and Only Functional Cure for Chronic Hepatitis B
August 25, 2026
LONDON, England, Aug. 25 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Aug. 24, 2026:

* * *

Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B

* First global approval for Hibsago

* Chronic hepatitis B affects nearly one million people in Japan/1 with nationwide efforts for screening and treatment2

* Approval accelerated by SENKU d . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products